Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CGEN by emailGet an email when CGEN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CGEN, unsubscribe in one click. Privacy
📣 What CGEN Says Is Next
year end · “The guidance creates a comprehensive list of interim disclosures required under US GAAP and incorporates a disclosure principle that requires disclosures at interim periods when an event or change that has a material effect on an entity has occurred since the previous year end.”
Company press release, Aug 3, 2026 · SEC filing
first quarter of 2027 · “The Company anticipates the interim analysis with median progression-free survival data by the first quarter of 2027.”
Company press release, Aug 3, 2026 · SEC filing
first quarter of 2027 · “"Our MAIA-ovarian trial in platinum-sensitive ovarian cancer remains on track for the interim analysis with median progression-free survival data expected by the first quarter of 2027, which would mark a potential inflection point for COM701 in a patient population with a significant unmet need.”
Company press release, Aug 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CGEN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CGEN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.